

The Joint Nordic HTA-Bodies are well prepared for work under the EU HTA regulation

The joint Nordic HTA-Bodies (JNHB) are well prepared for work under the Health Technology Assessment (HTA) regulation and are excited that the HTA regulation will enter into application on January 12th, 2025. After working together for six years, JNHB has experience of joint assessments and foresee several benefits of the regulation.

From the JNHB-perspective, the major benefits of the HTA regulation are:

- The main work to determine a relevant comparator is conducted in each member state during the JCA PICO-process. Accordingly, the JNHB members will at an earlier stage than today know which products have common Nordic comparator and may be suitable for joint Nordic HTA.
- The JNHB will be able to have timely and focused contact with relevant HTDs aiming to prepare both HTDs and HTA-bodies for a joint Nordic assessment based on the JCA PICO.
- The relative effects of the intervention compared to relevant Nordic comparators are assessed during the JCA. Having this information available the JNHB team can focus on the health economic assessment, providing robust Nordic evaluations to base national decisions on reimbursement and recommendations on.
- The HTA-regulation and the JNHB will jointly facilitate harmonization and alignment across Nordic countries.

To align with the HTAR, JNHB will take cancer and ATMP products into special consideration from January 2025.

The Nordic countries have made national adaptations to comply with the HTA regulation. The national adaptations influence the JNHB process, and the Nordic HTA-bodies have a continuous dialogue about the consequences and benefits of these adaptations for the joint Nordic process. JNHB plan to update the JNHB process guideline and dossier template during 2025 for products with a JCA.

Read more about the work under the HTA regulation here [Latest updates - European Commission](#)

About the Nordic HTA-collaboration

The Nordic HTA collaboration was formerly called FINOSE. It started as a bottom-up initiative by the HTA authorities in Finland, Norway and Sweden and was launched in Stockholm in 2018. The collaboration extended to comprise Denmark in 2023 and Iceland in 2024 and consequently changed its name to Joint Nordic HTA-bodies, JNHB.

The basis for the collaboration is outlined in the Memorandum of Understanding, signed in April 2024 by the collaborating HTA bodies; the Danish Medicines Council (DMC), the Finnish Medicines Agency (Fimea), Landspítali - The National University Hospital of Iceland, the

Norwegian Medical Products Agency (NOMA) and the Dental and Pharmaceutical Benefits Agency (TLV) in Sweden.

Further information on the Joint Nordic HTA-Bodies can be found at www.jnhtabodies.org.
Members of the JNHB team can be reached by contact@jnhtabodies.org